We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An international trial evaluating Elixir Medical’s DynamX Bioadaptor drug-eluting coronary artery implant has completed enrollment of 444 patients across 35 centers in Japan, Europe and New Zealand, the company said.